Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trastuzumab Combined With Taxane Neoadjuvant Therapy for HER2-positive Breast Carcinoma in Situ: a Phase II Single-arm Clinical Study

NCT06843681 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT06843681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06843681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trastuzumab Combined With Taxane Neoadjuvant Therapy for HER2-positive Breast Carcinoma in Situ: a Phase II Single-arm Clinical Study
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
March 1, 2025
Completion date
January 1, 2030
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma in situ